Biomarkers for early detection of Alzheimer's disease (AD) and for monitoring treatment response are becoming critically important as novel pharmacotherapeutics emerge. Several candidate biochemical, anatomical, and functional biomarkers have shown promise for identifying disease risk or treatment response potential, but vary in their efficacy and invasiveness. Among these candidate biomarkers, task-activated functional magnetic resonance imaging (fMRI) is a promising approach that is noninvasive, carries little risk, and offers a high potential for identifying persons who may eventually develop AD. The purpose of this investigation is to examine the value of task-activated fMRI in the identification and prediction of disease course in populations at-risk for the development of mild cognitive impairment (MCI) or AD.
In specific Aim 1, we propose to examine the 7.0 year longitudinal course of 108 asymptomatic individuals with varying risk for conversion to MCI/AD based on the presence/absence of one or two apolipoprotein-E (APOE) e4 alleles and/or a family history of dementia, and of 24 patients with amnestic MCI (aMCI), a condition strongly associated with conversion to AD. Primary measures include fMRI using a semantic memory activation task involving famous name recognition, neurobehavioral testing, and brain morphometry. We hypothesize that baseline levels of brain activation and longitudinal changes in activation will be the strongest predictor of cognitive decline.
In Specific Aim 2, we propose to conduct a 24-week, randomized, double-blind, placebo-controlled, parallel group study of the Exelon(R) [rivastigmine] transdermal patch in 120 aMCI patients who have one or both APOE e4 alleles. Task-activated fMRI will serve as the primary biomarker of treatment efficacy along with neuropsychological testing and brain morphometry as secondary endpoints. We hypothesize that the treatment group will demonstrate a normalization (i.e. reduction) in the task-related neural activation pattern relative to the placebo group. In addition, we predict that change in task-activated fMRI magnitude will demonstrate greater sensitivity to cholinergic modulation than changes in neuropsychological testing and structural MRI. These studies offer the opportunity to determine the role of fMRI as a biomarker for predicting future decline in the latent and prodromal phase of AD as well as for monitoring therapeutic outcome in clinical trials.

Public Health Relevance

The early detection of Alzheimer's disease (AD) is critically important for developing effective therapies designed to delay or prevent neurodegeneration. Several candidate biochemical, anatomical, and functional biomarkers have shown promise for identifying disease risk or treatment response potential, but vary in their efficacy and invasiveness. Among these candidate biomarkers, task-activated functional magnetic resonance imaging (fMRI) is a promising approach that is noninvasive, carries little risk, and offers a high potential for identifying persons who may eventually develop AD. The purpose of this investigation is to examine the value of task-activated fMRI in the identification and prediction of disease course in populations at-risk for the development of mild cognitive impairment (MCI) or AD and for monitoring therapeutic outcome in clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
2R01AG022304-06A2
Application #
7782010
Study Section
Adult Psychopathology and Disorders of Aging Study Section (APDA)
Program Officer
Hsiao, John
Project Start
2003-05-15
Project End
2015-04-30
Budget Start
2010-05-15
Budget End
2011-04-30
Support Year
6
Fiscal Year
2010
Total Cost
$431,234
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Kelly, Dana A; Seidenberg, Michael; Reiter, Katherine et al. (2018) Differential 5-year brain atrophy rates in cognitively declining and stable APOE-?4 elders. Neuropsychology 32:647-653
Reiter, Katherine; Nielson, Kristy A; Durgerian, Sally et al. (2017) Five-Year Longitudinal Brain Volume Change in Healthy Elders at Genetic Risk for Alzheimer's Disease. J Alzheimers Dis 55:1363-1377
Kay, Christina D; Seidenberg, Michael; Durgerian, Sally et al. (2017) Motor timing intraindividual variability in amnestic mild cognitive impairment and cognitively intact elders at genetic risk for Alzheimer's disease. J Clin Exp Neuropsychol 39:866-875
Lowe, Mark J; Sakaie, Ken E; Beall, Erik B et al. (2016) Modern Methods for Interrogating the Human Connectome. J Int Neuropsychol Soc 22:105-19
Smith, J Carson; Lancaster, Melissa A; Nielson, Kristy A et al. (2016) Interactive effects of physical activity and APOE-?4 on white matter tract diffusivity in healthy elders. Neuroimage 131:102-12
Lancaster, Melissa A; Seidenberg, Michael; Smith, J Carson et al. (2016) Diffusion Tensor Imaging Predictors of Episodic Memory Decline in Healthy Elders at Genetic Risk for Alzheimer's Disease. J Int Neuropsychol Soc 22:1005-1015
Barch, Deanna M; Verfaellie, Mieke; Rao, Stephen M (2016) Introduction to JINS Special Issue on Human Brain Connectivity in the Modern Era: Relevance to Understanding Health and Disease. J Int Neuropsychol Soc 22:101-4
Carson Smith, J; Erickson, Kirk I; Rao, Stephen M (2015) Introduction to the JINS Special Issue: Physical Activity and Brain Plasticity. J Int Neuropsychol Soc 21:743-4
Rao, Stephen M; Bonner-Jackson, Aaron; Nielson, Kristy A et al. (2015) Genetic risk for Alzheimer's disease alters the five-year trajectory of semantic memory activation in cognitively intact elders. Neuroimage 111:136-46
Sugarman, Michael A; Woodard, John L; Nielson, Kristy A et al. (2014) Performance variability during a multitrial list-learning task as a predictor of future cognitive decline in healthy elders. J Clin Exp Neuropsychol 36:236-43

Showing the most recent 10 out of 32 publications